MECOM and acute myeloid leukemia: As in ICC – in contrast to WHO 2022 – RUNX1 mutations were qualifying mutations for AML-MR, 46 of the previous 48 (96%) AML-RUNX1 cases were classified as AML-MR while two had other MECOM-r.